Home
Eva Gerdts's picture

Eva Gerdts

Professor, Member Norwegian Academy of Science & Letters
  • E-mailEva.Gerdts@uib.no
  • Phone+47 55 97 30 54+47 920 86 505
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen

Heart disease in women is the main focus of all our research. The research involves international partnerships in Italy, Germany and USA. Different projects focus on heart disease due to high blood pressure, obesity, autoimmune diseases and aortic valve stenosis. Our research has so far contributed to the publication of European recommendations for treatment of high blood pressure in patients with aortic valve stenosis (2020) and a strong international focus on sex differences in heart disease through scientific publications, reviews and position papers in high-end journals including European Heart Journal, Nature Medicine and Hypertension. A new Centre for research on heart disease in women was established at UiB in June 2020 supported by Hjertefondet, Bergen Sanitetskvinner/Norske Kvinners Sanitetsforening and Grieg Foundation (https://www.uib.no/en/femaleheart). Our future research will be integrated with this new network.

The third survey in the Hordaland Health Study (HUSK3) is being performed from June 2018 until June 2022. The main focus is to explore the impact of change in blood pressure and other health factors when the participants were in their forties for cardiovascular health 20 years later. The HUSK3 project is a collaboration between 4 research groups at UiB chaired by Eva Gerdts, Grethe S. Tell, Ottar Nygård and Jutta Dierkes, the BEVITAL academic laboratory and professor Marjolein Iversen at the Western Norway University of Applied Sciences. Additional information may be found under: PhD student Ester A. Kringeland, UiB; PhD student Zoya Sabir, UiB

Uncontrolled high blood pressure is a major health challenge in Norway and a focus area for my research, in particular related to sex differences in how high blood pressure promote damage to the heart. From 2019 we participate in a new research collaboration between the 4 Norwegian Medical Faculties in Bergen, Oslo, Trondheim and Tromsø focusing on mechanisms for uncontrolled high blood pressure among patients who use blood pressure lowering drug treatment. This IDA study is funded by the Norwegian Research Council. At campus, we have also developed a local collaboration with consultant PhD Marianne Grytaas, Section for endocrinology, Haukeland University Hospital, Bergen, to study mechanisms of heart damage in patients with primary aldosteronism, a common cause of uncontrolled high blood pressure. In particular these studies will explore whether high blood pressure associated heart damage differs between women and men or depending on the etiology. See information on: PhD student Arleen Aune, UiB

Women with autoimmune diseases represent a high-risk group for development of premature heart disease. A research program on heart disease in autoimmune disorders have been developed in collaboration with national and international partners. From 2018 a research collaboration with Department of Rheumatology, Haukeland University Hospital has focused on the cardiac benefit of modern immunomodulating therapy for rheumatoid arthritis.  See information on: Postdoctoral fellow PhD Helga Midtbø, Haukeland University Hospital

A program targeting preclinical heart disease in young patients with ischemic stroke was initiated in 2012 in collaboration with professor Ulrike Waje-Andreassen, Department of Neurology, Haukeland University Hospital. The follow-up examinations will be completed in 2021. The program also includes an engagement from the Helsinki University Hospital to serve as echocardiography core laboratory in an European multicenter study in patients who suffer a cryptogenic stroke before the age of 50 years. See information on: Professor Ulrike Waje-Andreassen, UiB 

Academic article
  • Show author(s) 2014. No gender difference in the extent of myocardial ischemia in non-ST elevation myocardial infarction. European Journal of Preventive Cardiology (EJPC). 123-129.
  • Show author(s) 2013. The Norwegian stroke in the young study (NOR-SYS): rationale and design. BMC Neurology. 12 pages.
  • Show author(s) 2013. Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis study. International Journal of Cardiology. 72-76.
  • Show author(s) 2013. Prognostic Value of Energy Loss Index in Asymptomatic Aortic Stenosis. Circulation. 1149-1156.
  • Show author(s) 2013. Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: The LIFE study. American Journal of Hypertension. 567-573.
  • Show author(s) 2013. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. The Lancet. 14 pages.
  • Show author(s) 2013. Left atrial volume index as a marker of left ventricular diastolic dysfunction in asymptomatic Tanzanian diabetic patients. Blood Pressure. 86-93.
  • Show author(s) 2012. Left ventricular function in children and adults after renal transplantation in childhood. Pediatric nephrology (Berlin, West). 1565-1574.
  • Show author(s) 2012. Left Atrial Systolic Force and Outcome in Asymptomatic Mild to Moderate Aortic Stenosis. Echocardiography. 1038-1044.
  • Show author(s) 2012. Increased relative wall thickness is a marker of subclinical cardiac target-organ damage in African diabetic patients. Cardiovascular Journal of Africa. 435-441.
  • Show author(s) 2012. Global left ventricular load in asymptomatic aortic stenosis: covariates and prognostic implication (the SEAS trial). Cardiovascular Ultrasound.
  • Show author(s) 2012. Effect of bariatric surgery on left ventricular geometry and function in severe obesity. Obesity Research and Clinical Practice. E189-E196.
  • Show author(s) 2011. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart. 301-307.
  • Show author(s) 2010. Severe obstructive sleep apnea elicits concentric left ventricular geometry. Journal of Hypertension. 1074-1082.
  • Show author(s) 2010. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. Journal of Hypertension. 1534-1540.
  • Show author(s) 2010. Prognostic Significance of Left Ventricular Diastolic Dysfunction in Patients With Left Ventricular Hypertrophy and Systemic Hypertension (the LIFE Study). American Journal of Cardiology. 999-1005.
  • Show author(s) 2010. Myocardial deformation in aortic valve stenosis – relation to left ventricular geometry. Heart. 106-112.
  • Show author(s) 2010. Left atrial size and force in patients with systolic chronic heart failure: Comparison with healthy controls and different cardiac diseases. Experimental and clinical cardiology. e45-e51.
  • Show author(s) 2010. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Pressure. 169-175.
  • Show author(s) 2010. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. Journal of Hypertension. 1541-1546.
  • Show author(s) 2010. Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). Journal of Hypertension. 377-383.
  • Show author(s) 2010. Impact of Pressure Recovery on Echocardiographic Assessment of Asymptomatic Aortic Stenosis: A SEAS Substudy. Journal of the American College of Cardiology. 555-562.
  • Show author(s) 2010. Impact of Baseline Severity of Aortic Valve Stenosis on Effect of Intensive Lipid Lowering Therapy (from the SEAS Study). American Journal of Cardiology. 1634-1639.
  • Show author(s) 2010. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in aortic stenosis [SEAS] substudy). American Journal of Cardiology. 1456-1460.
  • Show author(s) 2010. Asymmetric septal hypertrophy - a marker of hypertension in aortic stenosis (a SEAS substudy). Blood Pressure. 140-144.
  • Show author(s) 2010. Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 1134-1140.
  • Show author(s) 2010. An unusual location of a papillary fibroelastoma. European Heart Journal-Cardiovascular Imaging.
  • Show author(s) 2009. Ultrasound in evaluation of post-interventional femoral vein obstruction: a case report. Cardiovascular Ultrasound. 14.
  • Show author(s) 2009. Quantitative contrast stress echocardiography in assessment of restenosis after percutaneous coronary intervention in stable coronary artery disease. European Heart Journal-Cardiovascular Imaging. 858-864.
  • Show author(s) 2009. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). Blood Pressure. 180-186.
  • Show author(s) 2009. Myocardial Contrast Echocardiography in Assessment of Stable Coronary Artery Disease at Intermediate Dobutamine-Induced Stress Level. Echocardiography. 52-60.
  • Show author(s) 2009. Mitral E Wave Deceleration Time to Peak E Velocity Ratio and Cardiovascular Outcome in Hypertensive Patients During Antihypertensive Treatment (from the LIFE Echo-Substudy). American Journal of Cardiology. 1098-1104.
  • Show author(s) 2009. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. JACC Cardiovascular Imaging. 390-399.
  • Show author(s) 2009. Left ventricular long-axis function in treated haemochromatosis. The International Journal of Cardiac Imaging. 237-247.
  • Show author(s) 2009. Left ventricular diastolic function in patients with treated haemochromatosis. Scandinavian Cardiovascular Journal. 32-38.
  • Show author(s) 2009. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. NMCD. Nutrition Metabolism and Cardiovascular Diseases. 306-312.
  • Show author(s) 2009. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. European Journal of Cardiovascular Prevention & Rehabilitation. 242-248.
  • Show author(s) 2009. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. NMCD. Nutrition Metabolism and Cardiovascular Diseases. 634-640.
  • Show author(s) 2009. Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. NMCD. Nutrition Metabolism and Cardiovascular Diseases. 634-640.
  • Show author(s) 2008. Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania. Cardiovascular Journal of Africa. 8-14.
  • Show author(s) 2008. Left ventricular structure in different types of chronic pressure overload. European Heart Journal, Supplement. E23-E30.
  • Show author(s) 2008. Left atrial volume in patients with asymptomatic aortic valve stenosis (the simvastatin and ezetimibe in aortic stenosis study). American Journal of Cardiology. 1030-1034.
  • Show author(s) 2008. Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension. 1472-1476.
  • Show author(s) 2008. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. New England Journal of Medicine. 1343-1356.
  • Show author(s) 2008. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). European Heart Journal-Cardiovascular Imaging. 809-815.
  • Show author(s) 2008. Gender differences in left ventricular structure and function during antihypertensive treatment - The Losartan intervention for Endpoint reduction in hypertension study. Hypertension. 1109-1114.
  • Show author(s) 2008. Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy in Response to Antihypertensive Therapy. Hypertension. 100-106.
  • Show author(s) 2008. Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy. Hypertension. 100-106.
  • Show author(s) 2008. Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS substudy). American Journal of Cardiology. 510-515.
  • Show author(s) 2008. Effects of Losartan in women with hypertension and left ventricular hypertrophy results from the Losartan Intervention For Endpoint Reduction in hypertension study. Hypertension. 1103-1108.
  • Show author(s) 2008. Clinical impact of ' in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension. 806-812.
  • Show author(s) 2008. Brain abscess caused by paradoxical embolization in Ebstein's anomaly. European Heart Journal-Cardiovascular Imaging. 105-106.
  • Show author(s) 2007. Reduced exercise capacity in genetic haemochromatosis. European Journal of Cardiovascular Prevention & Rehabilitation. 470-475.
  • Show author(s) 2007. Left atrial size and risk of major cardiovascular events during antihypertensive treatment - Losartan intervention for endpoint reduction in hypertension trial. Hypertension. 311-316.
  • Show author(s) 2007. Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. American Journal of Hypertension. 771-776.
  • Show author(s) 2007. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. American Journal of Cardiology. 970-973.
  • Show author(s) 2006. Impact of hypertension on left ventricular hypertrophy regression and exercise capacity in patients operated for aortic valve stenosis. Scandinavian Cardiovascular Journal. 167-174.
  • Show author(s) 2006. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy - The Losartan Intervention for Endpoint (LIFE) Reduction in Hypertension Study. Circulation. 1588-1596.
  • Show author(s) 2006. Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Blood Pressure. 220-226.
  • Show author(s) 2005. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology. 705-711.
  • Show author(s) 2005. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology. 712-719.
  • Show author(s) 2004. Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension. 423-430.
  • Show author(s) 2004. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. Journal of Human Hypertension. 411-416.
  • Show author(s) 2004. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. American Heart Journal. 538-544.
  • Show author(s) 2004. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol - The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 1456-1462.
  • Show author(s) 2004. Prognostic significance of left ventricular mass change during treatment of hypertension. Journal of the American Medical Association (JAMA). 2350-2356.
  • Show author(s) 2004. Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension. 411-416.
  • Show author(s) 2004. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). Journal of Human Hypertension. 417-422.
  • Show author(s) 2004. Hypertensjon og hjertesykdom. Tidsskrift for Den norske legeforening. 802-805.
  • Show author(s) 2004. Essential hypertension in women. Blood Pressure. 272-278.
  • Show author(s) 2004. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). American Journal of Cardiology. 1076-1080.
  • Show author(s) 2004. Blood pressure measurements by the Keito machine. Evaluation versus office blood pressure by physicians. Blood Pressure Monitoring. 167-172.
  • Show author(s) 2004. Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Human Hypertension. 397-402.
  • Show author(s) 2004. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. Journal of Human Hypertension. 453-459.
  • Show author(s) 2003. Pulse pressure/stroke index and left ventricular geometry and function:the Life Study. Journal of Hypertension. 781-787.
  • Show author(s) 2003. Left ventricular mass regression in the life study: effect of previous antihypertensive treatment. American Journal of Hypertension. 180-186.
  • Show author(s) 2003. Hjertesykdom ved genetisk hemokromatose. Hjerteforum. 16-20.
  • Show author(s) 2003. Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiograaphhic left ventricular hypertrophy The life study. Hypertension. 75-82.
  • Show author(s) 2002. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. American Heart Journal. 319-326.
  • Show author(s) 2002. Sex differences in left ventricular systolic function. Cardiology Review. 29-32.
  • Show author(s) 2002. Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). American Journal of Cardiology. 337-341.
  • Show author(s) 2002. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. Journal of Hypertension. 1445-1450.
  • Show author(s) 2002. Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). Journal of Hypertension. 1223-1229.
  • Show author(s) 2002. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). American Journal of Cardiology. 399-402.
  • Show author(s) 2002. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension. 739-743.
  • Show author(s) 2002. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 227-232.
  • Show author(s) 2002. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation. 1071-1076.
  • Show author(s) 2002. Bruk av ekkokardiografi i hypertensjonsstudier. Hjerteforum. 77-83.
  • Show author(s) 2001. Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study. American Journal of Hypertension. 768-774.
  • Show author(s) 2001. Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus. Kidney and Blood Pressure Research. 64-70.
  • Show author(s) 2001. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Journal of Hypertension. 127-134.
  • Show author(s) 2001. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. American Heart Journal. 784-791.
  • Show author(s) 2001. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). American Journal of Cardiology. 980-983.
  • Show author(s) 2001. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Pressure. 74-82.
  • Show author(s) 2000. Left ventricular wall stresses and stress-mass products in hypertensive patients with electrocardiographic left ventricular hypertrophy. Journal of Hypertension. 1129-1138.
  • Show author(s) 2000. Left ventricular wall stresses and stress-mass products in hypertensive patients with electrocardiographic left ventricular hypertrophy. Journal of Hypertension. 1129-1138.
  • Show author(s) 2000. Left ventricular diastolic filling patterns in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. American Journal of Cardiology. 466-472.
  • Show author(s) 2000. Left ventricular diastolic filling patterns in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. American Journal of Cardiology. 466-472.
  • Show author(s) 2000. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE Study. Hypertension. 6-12.
  • Show author(s) 2000. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE Study. Hypertension. 6-12.
  • Show author(s) 2000. HOPE ett år senere. Hjerteforum. 31-35.
  • Show author(s) 2000. HOPE ett år senere. Hjerteforum. 31-35.
  • Show author(s) 1999. Similar central hemodynamics in salt sensitive and salt resistant hypertensive patients. Blood Pressure. 233-241.
  • Show author(s) 1999. Early complications and long-term mortality after urgent or routine coronary angioplasty. Scandinavian Cardiovascular Journal. 33.
  • Show author(s) 1998. Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for months months. American Journal of Hypertension. 1178-1187.
  • Show author(s) 1998. Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using Captopril or Doxazosin for months. American Journal of Hypertension. 1178-1187.
  • Show author(s) 1997. Regression of left ventricular hypertrophy in type-1 diabetic patients using doxazosin as antihypertensive therapy @<abstract@>. Journal of Hypertension. 40.
  • Show author(s) 1997. Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
  • Show author(s) 1997. Factors influencing LVM in hypertensitive type-1 diabetic patients. Blood Pressure. 197-202.
  • Show author(s) 1997. Angiotensin converting enzyme inhibition and alpha<SUB>1</SUB>-receptor blockade as antihypertensive therapy in type-1 diabetic patients. American Journal of Hypertension. 121A.
  • Show author(s) 1996. Salt sensitivity in hypertensive type-1 diabetes mellitus. Blood Pressure. 78-85.
  • Show author(s) 1996. Salt sensitivity in hypertensive type-1 diabetes mellitus. Blood Pressure. 78-85.
  • Show author(s) 1996. Factors influencing left ventricular mass in hypertensive type-1 diabetic patients. American Journal of Hypertension. 65A.
  • Show author(s) 1994. Salt sensitive essential hyperdension evaluated by 24 hour ambulatory blood pressure. Blood Pressure. 375-380.
  • Show author(s) 1994. Postoperative Doppler echocardiograpic evaluation in different sizes of Medtronic-Hall, Biocor and Carpentier-Edwards s.a.v. prosthetic-aortic valves. Scandinavian journal of thoracic and cardiovascular surgery. 25-29.
Academic lecture
  • Show author(s) 2003. Left atrial size and risk of major cardiovascular events in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE trial).
  • Show author(s) 2002. The impact of concomitant diabtes on changes in left ventricular structure and function during antihypertensive treatment (the LIFE study).
  • Show author(s) 2002. Endocardial as well as midwll fractional shortening predict cardiovascular outcome in hypertension: The LIFE study.
  • Show author(s) 2001. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the LIFE study.
  • Show author(s) 2000. The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
  • Show author(s) 2000. The effect of losartan treatment on left ventricular hypertrophy in patients with essential hypertension.
  • Show author(s) 2000. Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
  • Show author(s) 2000. Reduction in left ventricular mass and blood pressure is not accompanied by improved exercise performance in hypertensive patients with left ventricular hypertrophy.
  • Show author(s) 2000. Parallel cardiac and renal damage in patients with left ventricular hypertrophy.
  • Show author(s) 2000. Parallel cardiac and renal damage in patients with left ventricular hypertrophy.
  • Show author(s) 2000. Inappropriate left ventricular mass is associated with high cardiovascular risk profile in hypertensive subjects.
  • Show author(s) 2000. Inappropriate left ventricular mass is associated with high cardiovascular risk profile in hypertensive subjects.
  • Show author(s) 2000. In hypertensive patients with left ventricular hypertrophy inappropriate left ventricular mass identifies high risk phenotypes.
  • Show author(s) 2000. In hypertensive patients with left ventricular hypertrophy inappropriate left ventricular mass identifies high risk phenotypes.
  • Show author(s) 2000. Change in diastolic left ventricular function after one year of antihypertensive treatment.
  • Show author(s) 2000. Change in diastolic left ventricular function after one year of antihypertensive treatment.
  • Show author(s) 2000. Antihypertensive therapy has greater impact on left ventrular hypertrophy reduction in women than men.
  • Show author(s) 2000. Antihypertensive therapy has greater impact on left ventrular hypertrophy reduction in women than men.
  • Show author(s) 1997. Hypertensive women with electrocardiographic left ventricular hypertrophy have Doppler echocardiographic indications of more impaired diastolic left ventricular function compared to men, at rest and during exercise.
  • Show author(s) 1996. Salt sensitivity in hypertensive type-1 diabetes mellitus.
  • Show author(s) 1996. Factors influencing left ventricular mass in hypertense type-1 diabetic patients.
  • Show author(s) 1995. Factors influencing the regression of left ventricular mass in men and women operated for aortic stenosis.
  • Show author(s) 1994. Plasma atial natriuretic peptide in salt sensitive hypertensive patients.
Abstract
  • Show author(s) 2014. Determinants of left ventricular systolic function after transcatheter aortic valve implantation. European Heart Journal-Cardiovascular Imaging.
  • Show author(s) 2013. Outcome in 1763 asymptomatic patients with mild or moderate calcific aortic stenosis followed prospectively with annual echocardiography. European Heart Journal. 334-334.
  • Show author(s) 2013. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment in patients with electrocardiographic left ventricular hypertrophy (LIFE). European Heart Journal. 597-597.
  • Show author(s) 2013. Hypertensive target organ damage predicts incident diabetes mellitus. European Heart Journal. 3419-3426.
  • Show author(s) 2013. Does rheumatoid arthritis predispose to abnormal left ventricular geometry independent of hypertension? European Heart Journal. 754-754.
  • Show author(s) 2013. Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry. Arthritis and Rheumatism. S182-S182.
  • Show author(s) 2013. Coronary artery plaque burden is a predictor of myocardial ischemia in non-ST elevation myocardial infarction in both genders. European Heart Journal. 74-75.
  • Show author(s) 2013. Arterial Stiffness Is Associated With Abnormal Left Ventricular Geometry In Patients With Rheumatoid Arthritis. Arthritis and Rheumatism. S174-S175.
  • Show author(s) 2012. Midwall left ventricular systolic function in asymptomatic aortic valve stenosis: is it prognostically important? The SEAS study. European Heart Journal. 97-98.
  • Show author(s) 2012. Covariates of global longitudinal strain and displacement in type 2 diabetes: a speckle tracking echocardiography study. European Heart Journal. 454-454.
  • Show author(s) 2011. Increased systolic strain rate early after transcatheter aortic valve implantation. European Heart Journal-Cardiovascular Imaging. ii37-ii37.
  • Show author(s) 2011. Impact of valvuloarterial impedance on cardiovascular outcome in patients with asymptomatic aortic stenosis. The SEAS study. Circulation.
  • Show author(s) 2011. Impact of aortic valve stenosis and hypertension on radial strain in multiple layers. European Heart Journal, Supplement. 1008-1009.
  • Show author(s) 2010. Risk factors for unexpected sudden death in patients with non-symptomatic aortic stenosis (the SEAS study). European Heart Journal. 886-887.
  • Show author(s) 2010. Left ventricular mass, an independent predictor of morbidity and mortality in aortic valve stenosis. European Heart Journal. 887-887.
  • Show author(s) 2010. Increased Relative Wall Thickness - A Frequent Marker of Subclinical Cardiac Target Organ Damage in African Diabetic Patients. Journal of Hypertension. E357-E357.
  • Show author(s) 2010. Hypoperfusion by contrast echocardiography predicts coronary artery disease severity in non-ST elevation myocardial infarction. European Heart Journal. 914-914.
  • Show author(s) 2010. Hypokalemi blunts left ventricular mass regression in hypertensive patients during losartan- or atenolol-based treatmend: The LIFE echo-substudy. Journal of Hypertension. E442-E443.
  • Show author(s) 2010. COMBINED USE OF ELECTROCARDIOGRAM AND ECHOCARDIOGRAM TO BETTER IDENTIFY HYPERTENSIVE PATIENTS AT HIGH RISK FOR HEART FAILURE. Journal of Hypertension. E214-E214.
  • Show author(s) 2009. Relation of degree of aortic valve calcification to left ventricular geometry and systolic function in asymptomatic aortic valve stenosis: A SEAS substudy. Journal of the American College of Cardiology. A410-A410.
  • Show author(s) 2009. Outcome of Asymptomatic Patients With Low Gradient "Severe" Aortic Valve Stenosis and Preserved Ejection Fraction - Results From the Prospective SEAS Study. Circulation. S371-S371.
  • Show author(s) 2009. Impact of severity of aortic valve stenosis on effect of intensive lipid-lowering therapy: The SEAS study. Journal of the American College of Cardiology. A415-A415.
  • Show author(s) 2009. ISOLATED SYSTOLIC HYPERTENSION IN PATIENTS WITH ASYMPTOMATIC AORTIC STENOSIS (A SEAS SUBSTUDY). Journal of Hypertension. S248-S248.
  • Show author(s) 2009. IMPACT OF STROKE VOLUME ON CARDIOVASCULAR RISK IN HYPERTENSIVE PATIENTS WITH ELECTROCARDIOGRAPHIC LEFT VENTRICULAR HYPERTROPHY (A LIFE SUBSTUDY). Journal of Hypertension. S319-S320.
  • Show author(s) 2009. Gender Differences in Outcome During Antihypertensive Therapy in Relation to Regression of Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study. Circulation. S1111-S1111.
  • Show author(s) 2009. Development of Systolic Dysfunction Not Related to Myocardial Infarction in Treated Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Echo Substudy. Circulation. S1164-S1165.
  • Show author(s) 2009. Compensatory or inappropriate left ventricular mass in asymptomatic aortic stenosis. Journal of the American College of Cardiology. A408-A409.
  • Show author(s) 2009. 2D Longitudinal Myocardial Strain: A More Sensitive Parameter of Left Ventricular Dysfunction in Aortic Valve Stenosis? Circulation. S372-S373.
  • Show author(s) 2008. The differential impact of static and pulsatile blood pressure components on regional myocardial deformation in patients with asymptomatic aortic valve stenosis. A SEAS substudy. Journal of Hypertension. S255-S256.
  • Show author(s) 2008. Impact of global afterload on left ventricular myocardial contractility in asymptomatic aortic stenosis: A SEAS substudy. Journal of the American College of Cardiology. A380-A380.
  • Show author(s) 2008. Impact of Pressure Recovery on Diagnosis of Severe Aortic Stenosis In Asymptomatic Patients. (A SEAS Substudy). Circulation. S931-S931.
  • Show author(s) 2008. Gender differences in left ventricular structure and function during antihypertensive treatment (the LIFE study). Journal of Hypertension. S275-S275.
  • Show author(s) 2007. Relationship of left ventricular Systolic function to persistence or development,of Electrocardiographic left ventricular hypertrophy in hypertensive patients: Implications for the development of new heart failure. Circulation. 473-473.
  • Show author(s) 2007. Pulse pressure - An independent predictor of left ventricular hyperthrophy in patients with asymptomatic aortic stenosis. A SEAS substudy. Circulation. 671-671.
  • Show author(s) 2007. Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during anti-hypertensive treatment: The LIFE echo-substudy. Circulation. 498-498.
  • Show author(s) 2007. Impact of left ventricular geometry on stress-corrected left ventricular systolic function in asymptomatic aortic valve stenosis. A SEAS substudy. Journal of the American College of Cardiology. 298A-299A.
  • Show author(s) 2007. Gender difference in the association of aortic valve sclerosis and cardiovascular events in hypertensive adults with left ventricular hypertrophy: The LIFE study. Circulation. 735-735.
  • Show author(s) 2007. Does metabolic syndrome influence reduction of ECG left ventricular hypertrophy? The LIFE study. Journal of Hypertension. S78-S78.
  • Show author(s) 2007. Association of aortic regurgitation with cardiovascular morbidity and mortality in hypertensive patients with left ventricle hypertrophy: The LIFE study. Circulation. 735-735.
  • Show author(s) 2006. Relationship of left atrial enlargement to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. Circulation. 366-366.
  • Show author(s) 2006. Prevalence and covariates of low left ventricular midwall shortening in patients with asymptomatic aortic valve stenosis. A SEAS substudy. Circulation. 656-657.
  • Show author(s) 2006. Impact of gender on left atrial and ventricular response to asymptornatic aortic valve stenosis. The SEAS study. Journal of the American College of Cardiology. 285A-286A.
  • Show author(s) 2005. Relationship of electrocardiographic strain pattern to left ventricular diastolic function in hypertensive patients: The LIFE study. Journal of the American College of Cardiology.
  • Show author(s) 2005. Influence of hypertension on angiographic findings in patients with angina pectoris. American Journal of Hypertension. 175A.
  • Show author(s) 2005. Impact of concomitant hypertension on left ventricular structure in patients with aortic valve stenosis. The SEAS study. European Heart Journal-Cardiovascular Imaging. S76.
  • Show author(s) 2005. Echocardiographic determinants of new-onset atrial fibrillation in patients with hypertension and electrocardiographic left ventricular hypertrophy: The LIFE study. Journal of the American College of Cardiology.
  • Show author(s) 2004. Tissue Doppler findings in patients with genetic hemochromatosis. Hjerteforum. 101.
  • Show author(s) 2004. Pulse pressure as cardiovascular risk marker during losartan or atenolol based therapy in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Trial). Journal of the American College of Cardiology. 448A.
  • Show author(s) 2004. Myocardial performance index independently predicts cardiovascular morbidity and mortality in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Journal of the American College of Cardiology. 227A.
  • Show author(s) 2004. Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Journal of the American College of Cardiology. 357A.
  • Show author(s) 2004. Ethnicity, left ventricular hypertrophy regressio and cardiovascular events in the LIFE echocardiography substudy. American Journal of Hypertension. A195.
  • Show author(s) 2004. Does losartan improve diastolic left ventricular function beetter than atenolol during more then four years of antihypertensive treatment? The LIFE Study. Circulation. 637.
  • Show author(s) 2004. Clinical and echocardiographic risk factors for congestive heart failure in controlled hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Study). Circulation. 682-682.
  • Show author(s) 2004. Blood pressure and cardiovascular risk factors in hypertensive patients referred to a regional hospital in Ghana. American Journal of Hypertension. A196.
Academic literature review
  • Show author(s) 2020. Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy.
  • Show author(s) 2019. Sex differences in cardiometabolic disorders. Nature Medicine. 1657-1666.
  • Show author(s) 2018. Managing complications of hypertension in aortic valve stenosis patients. Expert Review of Cardiovascular Therapy. 897-907.
  • Show author(s) 2016. Epidemiology of left ventricular hypertrophy in hypertension: implications for the clinic. Expert Review of Cardiovascular Therapy. 915-926.
  • Show author(s) 2016. Atherosclerosis in Sjögren's syndrome: Evidence, possible mechanisms and knowledge gaps. Clinical and Experimental Rheumatology. 133-142.
  • Show author(s) 2013. Left ventricular geometry in obesity: Is it what we expect? NMCD. Nutrition Metabolism and Cardiovascular Diseases. 905-912.
  • Show author(s) 2010. Impact of ultrasound contrast agents in echocardiographic assessment of ischemic heart disease. Recent patents on cardiovascular drug discovery. 103-112.
  • Show author(s) 2004. Essential hypertension in women. Blood Pressure. 272-278.

More information in national current research information system (CRIStin)

FEMALE HEART project

International collaboration from 2012 with researchers at UiT The Arctic University of Norway and federico II University of Naples, Italy. Translational project involving experimental animal studies and clinical studies. The project aim to identify mechanisms for why high blood pressure is more damaging to the heart in women than in men. An annual Female Heart workshop is organized at UiB based on this collaboration. 

Hordaland Health Study - 3rd survey (HUSK3)

Focus on how blood pressure in 40 years old women and men predicts their cardiovascular health 20 years later. Follow up of 3000 individuals.

FAT associated cardiovascular dysfunction (FATCOR)

Focus on how obesity influences cardiac and arterial function in women and men. Crossectional study of 620 individuals.

The IDA study

Focuses on mechanisms for uncontrolled high blood pressure in patients who are perscribed antihypertensive drugs. Estimated 1000 participants. National Norwegian research project.

Sex differences and hypertension in aortic stenosis

Based upon 1873 patients with aortic valve stenosis who participated in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study.